In addition, for patients with advanced NSCLC, it has been shown that the bispecific antibody AK112 works by targeting both PD-1 and VEGF and can be combined with chemotherapeutic agents to achieve a good anti-tumor effect (143, 144). This evidence concerns the gene VEGFA and neoplasm.